Bastert G, Schmidt-Matthiesen H, Gerner R, Michel R T, Nord D, Leppien G
Dtsch Med Wochenschr. 1975 Oct 3;100(40):2035-42. doi: 10.1055/s-0028-1106497.
In-vitro sensitivity to cystostatic agents was tested in 137 cases of breast carcinoma, with 125 tests being analysable. Inhibition of in-vitro incorporation of 3H-uridine or 3H-thymidine into RNA or DNA of the original tumour cells after incubation with antineoplastic substances was used as the index for the in-vivo sensitivity of the tumour. 30% of the carcinoma cells were sensitive in-vitro, 70% resistant. About 75% of sensitive cancers were sensitive against several agents. Cyclophosphamide proved to be most effective in-vitro: it was tested via 4-hydroxycyclophosphamide or 4-hydroperoxycyclophosphamide. There was a correlation between histological type and in-vitro sensitivity of the cancer, as well as between proliferative activity and in-vitro sensitivity in that proliferation-active tumours were more frequently sensitive in-vitro than proliferation-poor ones. Primary tumours and metastases of the same patient frequently showed different sensitivity. In some cases the development of resistance against cytostatic drugs was demonstrated during treatment. Testing tumours against combinations of cytostatic drugs demonstrated an additive effect of the antineoplastic substances in-vitro.
对137例乳腺癌患者的肿瘤细胞进行了体外抑癌药物敏感性测试，其中125例测试结果可用于分析。以抗肿瘤物质孵育后，原代肿瘤细胞中3H-尿苷或3H-胸苷掺入RNA或DNA的体外抑制率作为肿瘤体内敏感性的指标。30%的癌细胞在体外敏感，70%耐药。约75%的敏感癌对多种药物敏感。环磷酰胺在体外显示出最高疗效：通过4-羟基环磷酰胺或4-氢过氧环磷酰胺进行测试。癌组织学类型与体外敏感性之间、增殖活性与体外敏感性之间存在相关性，即增殖活跃的肿瘤比增殖不良的肿瘤在体外更常表现为敏感。同一患者的原发肿瘤和转移灶常常表现出不同的敏感性。在某些病例中，治疗期间显示出对细胞毒性药物产生耐药性。对细胞毒性药物组合进行肿瘤测试显示，抗肿瘤物质在体外具有相加作用。
